The FDA originally approved Caprelsa (vandetanib) in 2011 for treating medullary thyroid cancer in patients whose disease has spread or cannot be surgically removed. At that time, the agency required ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback